G
Glenn F. Pierce
Researcher at Biogen Idec
Publications - 135
Citations - 9579
Glenn F. Pierce is an academic researcher from Biogen Idec. The author has contributed to research in topics: Haemophilia & Population. The author has an hindex of 39, co-authored 116 publications receiving 7773 citations.
Papers
More filters
Journal ArticleDOI
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response
Catherine S. Manno,Glenn F. Pierce,Valder R. Arruda,Bertil Glader,Margaret V. Ragni,Rasko Jj,Margareth C. Ozelo,Keith Hoots,Blatt P,Barbara A. Konkle,Michael D. Dake,Robin D. Kaye,Mahmood K. Razavi,A Zajko,James L. Zehnder,Pradip Rustagi,Hiroyuki Nakai,A Chew,Debra G.B. Leonard,Debra G.B. Leonard,J F Wright,Ruth Lessard,Jurg M. Sommer,Michael Tigges,Denise E. Sabatino,A Luk,Haiyan Jiang,Federico Mingozzi,Linda B. Couto,Hildegund C.J. Ertl,Katherine A. High,Katherine A. High,Mark A. Kay +32 more
TL;DR: In this article, a single portal vein infusion of a recombinant adeno-associated viral vector (rAAV) expressing canine Factor IX (F.IX) resulted in long-term expression of therapeutic levels of F.IX in dogs with severe hemophilia B.
Journal ArticleDOI
WFH Guidelines for the Management of Hemophilia, 3rd edition
Alok Srivastava,Elena Santagostino,Alison Dougall,Steve Kitchen,Megan Sutherland,Steven W. Pipe,Manuel Carcao,Johnny Mahlangu,Margaret V. Ragni,Jerzy Windyga,Adolfo Llinás,Nicholas J. Goddard,Richa Mohan,Pradeep M. Poonnoose,Brian M. Feldman,Sandra Zelman Lewis,H. Marijke van den Berg,Glenn F. Pierce +17 more
TL;DR: The WFH Guidelines for the Management of Hemophilia panelists and co-authors thank the panelists for their time and share their views on how to better understand and treat hemophilia.
Journal ArticleDOI
AAV5–Factor VIII Gene Transfer in Severe Hemophilia A
Savita Rangarajan,Liron Walsh,Will Lester,David Perry,Bella Madan,Michael Laffan,Hua Yu,Christian Vettermann,Glenn F. Pierce,Wing Yen Wong,K. John Pasi +10 more
TL;DR: The infusion of AAV5‐hFVIII‐SQ was associated with the sustained normalization of factor VIII activity level over a period of 1 year in six of seven participants who received a high dose, with stabilization of hemostasis and a profound reduction in factor VIII use in all seven participants.
Journal ArticleDOI
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Johnny Mahlangu,Jerry S. Powell,Margaret V. Ragni,Pratima Chowdary,Neil C. Josephson,Ingrid Pabinger,H. Hanabusa,Naresh Gupta,Roshni Kulkarni,Patrick F. Fogarty,David J. Perry,Amy D. Shapiro,K. John Pasi,Shashikant Apte,Ivan Nestorov,Haiyan Jiang,Shuanglian Li,Srividya Neelakantan,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Nigel Dodd,Karen Nugent,Gloria Vigliani,Alvin Luk,Aoife Brennan,Glenn F. Pierce +27 more
TL;DR: In this paper, the authors evaluated the safety, efficacy, and pharmacokinetics of recombinant FVIII Fc fusion protein (rFVIIIFc) for prophylaxis, treatment of acute bleeding, and perioperative hemostatic control in 165 previously treated males aged ≥12 years with severe hemophilia A.
Journal ArticleDOI
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B
Jerry S. Powell,K. John Pasi,Margaret V. Ragni,Margareth C. Ozelo,Leonard A. Valentino,Johnny Mahlangu,Neil C. Josephson,D. J. Perry,Marilyn J. Manco-Johnson,Shashikant Apte,Ross I. Baker,Godfrey Chi-Fung Chan,Nicolas Novitzky,Raymond S.M. Wong,Snejana Krassova,G. Allen,Haiyan Jiang,Alison Innes,Shuanglian Li,Lynda M. Cristiano,Jaya Goyal,Jurg M. Sommer,Jennifer A. Dumont,Karen Nugent,Gloria Vigliani,Aoife Brennan,Alvin Luk,Glenn F. Pierce +27 more
TL;DR: Prophylactic rFIXFc, administered every 1 to 2 weeks, resulted in low annualized bleeding rates in patients with hemophilia B, mostly consistent with those expected in the general population of patients withhemophilia.